HOME >> BIOLOGY >> NEWS
Plant's PICKLE gene may hold clue to cancer

WEST LAFAYETTE, Ind. -- Purdue University biochemist Joe Ogas set out to determine why pickle-shaped swellings developed on some laboratory plant roots. Instead, he stumbled upon a biochemical on/off switch that could help researchers better understand cancer and, at the same time, develop new oil crops.

"We were looking at genetically modified Arabidopsis plants, trying to understand root development," Ogas says. "What we found was something totally different that will help us understand how plant cells change identity. It will help explain how seeds throw a biochemical switch that turns them into seedlings."

Because the basic biochemistry behind cell development is similar in both plants and animals, Ogas' work attracted the attention of the National Institutes of Health (NIH). The NIH this spring awarded him a five-year, $1.1 million grant to pursue the biochemistry behind a single gene he discovered and named the "PICKLE gene" -- the gene that, when mutated, causes the root swellings. The results may help human health researchers understand and fight cancer, a disease in which cellular developmental controls go awry.

Ogas's work was published in a November 1999 article in the Proceedings of the National Academy of Sciences.

Based on his and other scientists' research, Ogas says plants depend on two biochemical switches as they change from seed to adult. He found that in germinating seeds with normal PICKLE genes, one switch turns on while the other turns off. The first switch turns on the development of characteristics for a mature plant, initiating root and shoot development. At the same time, the plant with the normal PICKLE gene produces a protein called chromatin remodeling factor, which flips the biochemical off-switch that stops the expression of embryo characteristics. The two switches operate independently.

In plants with an abnormal PICKLE gene, however, the plant can't make chromatin remo
'"/>

Contact: Rebecca J. Goetz
rjg@aes.purdue.edu
765-494-0461
Purdue University
4-Sep-2000


Page: 1 2

Related biology news :

1. Leader in cancer treatment and prevention research honored
2. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
3. Chemical derived from vitamin-E shows early promise as cancer drug
4. New molecular link key to cellular proteins involved in cancer progression, other diseases
5. Phase II trials of second-generation antisense cancer drug planned following successful early study
6. Trial shows which brain cancer patients benefit from temozolomide
7. Genetic differences might help distinguish thyroid cancers
8. Evidence builds for potential new cancer drug target
9. New sequence involved in DNA replication timing may aid in cancer detection
10. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
11. Cannabis may help combat cancer-causing herpes viruses

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... ... today announced that an extensive third-party assessment of the company’s security practices has ... measured against federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, ...
(Date:8/26/2020)... ... August 25, 2020 , ... ... solutions for drugs, biologics, cell and gene therapies, and consumer health products, today ... PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien ... announced that the U.S. Food and Drug Administration (FDA) has approved the company’s ... for the treatment of severe COVID-19. Approval of this IND allows Sentien to ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... Slone ... companies, has announced the placement of Julianne Averill , CPA, as Chief ... all financial operations and implementing key business strategies to accelerate Alveo’s growth as ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... is making available for free its new white paper – Simulated Transport ... testing into today’s biologics licensing application (BLA). In response, Modality Solutions shares ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... 2020 , ... eSource has long been touted as the solution to high ... eSource, the reasons it did not take off as quickly as people initially expected, ... is moving towards capturing data electronically for clinical trials and then repurposing it for ...
Breaking Biology Technology:
Cached News: